Statistics from Altmetric.com
We thank Dr Sheinberg and colleagues'1 for raising the issue of hepatobiliary disorders mentioned in the European Public Assessment Report (EPAR) but not included in the 24-week report.2 This was due to the following reasons. First, the general safety reporting scheme was based on common adverse events (≥2% among reported adverse events, seen in table 2 of the paper), and overall major safety indices such as comparison of total treatment-emergent adverse events and serious adverse events. The groups of adverse events were those that were usually expected (or considered to be expected) to occur with etanercept use, such as serious infections, malignancies or injection site reactions. All of these were discussed in the 24-week paper. The imbalance of system organ class (SOC) hepatobiliary disorders found in the SB4 treatment group did not fit into any of these categories, as each distinct hepatobiliary event (such as bile duct stone, etc.) did not occur frequently enough to be ≥2%, and also did not fit into the categories of serious infections, malignancies or injection site reactions. Second, the distribution of the adverse events from SOC hepatobiliary disorders was not clinically homogenous and was considered a mixture of two distinct areas of drug safety: either the potential for increased drug-related hepatocellular toxicity, or the propensity for increased risk for bile stones; so that reporting the 11 patients as a whole would have been misleading. When considering each area, among the 11 patients identified, only 3 patients purely belonged to the hepatocellular category. This was not considered to be a substantial difference, and as also seen in table 2, from the 24-week report, the incidence of alanine transaminase and asparate transaminase increases reported as an adverse event was comparable between the SB4 and reference etanercept (ETN) treatment groups (5.0% vs 4.7% and 2.3% vs 2.7%, respectively). Of the remaining eight patients who had biliary events, two were found incidentally to have asymptomatic gallstones, after sonographic evaluation ordered for elevated liver enzymes. Therefore, the numerical imbalance is smaller than initially thought. Third, these patients usually had a biliary risk factor at baseline, such as older age, obesity, prior history of gallstones, medications or comorbidities, including cardiovascular risk/disease.3–5 When systematically analysed at the whole population level by baseline medical history and concomitant medications, there was a modest but generally higher trend of these biliary risk factors in the SB4 treatment group compared with the ETN treatment group (table 1), and this trend was considered to explain the substantial proportion of biliary risk of the SB4 population. Therefore, it was considered that the higher occurrence of biliary events was likely to be due to chance rather than to true SB4 causality, this was commented on in the EPAR.
As the 11 patients were heterogeneous in terms of safety classification, and the strength of causality for increased biliary risk by SB4 was questionable, it was felt inappropriate for us to discuss the imbalance of the SOC hepatobiliary disorders in the 24-week paper. It is to be noted that no additional hepatic or biliary risk was found beyond what was described in the EPAR, up to the end of the 100-week extension study. It is our opinion that extra surveillance for gallstones when treating patients with SB4 does not seem to be necessary, although the sponsor will monitor for this.
We hope that this will reassure Dr Scheinberg and colleagues for the safety of SB4, as well as to help maintain his enthusiasm on biosimilars.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.